doi: 10.1111/trf.14871.
Epub 2018 Sep 28.
How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation
Affiliations
- PMID: 30403414
- PMCID: PMC6911356
- DOI: 10.1111/trf.14871
Item in Clipboard
How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation
Transfusion.
2018 Nov.
Abstract
Multiple hematopoietic progenitor cell (HPC) transplantation options for patients with sickle cell disease (SCD) are currently under investigation. Patients with SCD have a high rate of alloimmunization to red blood cell antigens, often complicating transfusion support. Transfusion reactions, including acute and delayed hemolytic reactions, have been observed despite immunosuppressive regimens. Allogeneic donor transplants have been shown to carry a risk of prolonged reticulocytopenia and acute hemolysis with severe anemia in nonmyeloablative regimens. We discuss our experience providing transfusion support to patients with SCD undergoing HPC transplantation, propose an outline for a complete pretransplantation evaluation, and discuss donor/recipient compatibility issues and their implications.
Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
Conflict of interest statement
CONFLICT OF INTEREST
The authors have disclosed no conflicts of interest.
Figures
Template for a transfusion medicine consultation in the pretransplantation setting for a patient with SCD.
Similar articles
-
Effect of ABO Mismatch and Red Blood Cell Alloimmunization on the Outcome of Hematopoietic Cell Transplantation for Sickle Cell Disease.Transplant Cell Ther. 2025 Jan;31(1):30.e1-30.e8. doi: 10.1016/j.jtct.2024.11.003. Epub 2024 Nov 8. Transplant Cell Ther. 2025. PMID: 39522720
-
Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell Disease.Transplant Cell Ther. 2025 May;31(5):305-318. doi: 10.1016/j.jtct.2025.02.021. Epub 2025 Feb 24. Transplant Cell Ther. 2025. PMID: 40010689
-
Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.JAMA. 2014 Jul 2;312(1):48-56. doi: 10.1001/jama.2014.7192. JAMA. 2014. PMID: 25058217 Free PMC article. Clinical Trial.
-
Will developments in allogeneic transplantation influence treatment of adult patients with sickle cell disease?Biol Blood Marrow Transplant. 2004 Jan;10(1):23-31. doi: 10.1016/j.bbmt.2003.09.004. Biol Blood Marrow Transplant. 2004. PMID: 14752776 Review.
-
Allogenic hematopoietic stem cell transplantation in sickle cell disease.Transfus Apher Sci. 2021 Feb;60(1):103057. doi: 10.1016/j.transci.2021.103057. Epub 2021 Jan 10. Transfus Apher Sci. 2021. PMID: 33485798 Review.
Cited by
-
Alloimmunization and hyperhemolysis in sickle cell disease.Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):653-659. doi: 10.1182/hematology.2023000499. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066873 Free PMC article.
-
Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.Blood Adv. 2022 Apr 26;6(8):2707-2721. doi: 10.1182/bloodadvances.2021006279. Blood Adv. 2022. PMID: 34972204 Free PMC article. Review.
-
Longitudinal outcomes of chronically transfused adults with sickle cell disease and a history of childhood stroke.Transfusion. 2024 Dec;64(12):2260-2269. doi: 10.1111/trf.18041. Epub 2024 Nov 5. Transfusion. 2024. PMID: 39501512 Free PMC article.
-
Commentary: Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia.Front Immunol. 2023 Jan 27;14:1133382. doi: 10.3389/fimmu.2023.1133382. eCollection 2023. Front Immunol. 2023. PMID: 36776872 Free PMC article. No abstract available.
-
The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study.EClinicalMedicine. 2020 Jun 28;24:100432. doi: 10.1016/j.eclinm.2020.100432. eCollection 2020 Jul. EClinicalMedicine. 2020. PMID: 32637902 Free PMC article.
References
-
- Arnold SD, Bhatia M, Horan J, et al. Haematopoietic stem cell transplantation for sickle cell disease — current practice and new approaches. Br J Haematol 2016;174:515–25. - PubMed
-
- McPherson ME, Anderson AR, Haight AE, et al. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor. Transfusion 2009;49: 1977–86. - PubMed
-
- Klein HG, Anstee DJ. Mollison’s blood transfusion in clinical medicine. 12th ed. Malden (MA): Wiley & Sons, Ltd; 2014.
-
- Evidence-based management of sickle cell disease: expert panel report, 2014. Bethesda: U.S. Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute; 2014.
